By Gina Shaw
Innovative pharmacy benefits manager (PBM) Abarca has entered into an outcomes-based contract for the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab (Repatha) with manufacturer Amgen, the first such agreement for the drug with a stand-alone PBM.
“We agreed on behalf of our clients to cover this medication as a specific line of defense to treat patients at high risk for cardiovascular events that require a more aggressive lowering of LDL cholesterol